Ryan Bartolucci Sells 2,902 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 2,902 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $171,363.10. Following the completion of the transaction, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. This trade represents a 6.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Tempus AI Stock Down 2.7%

NASDAQ:TEM traded down $1.59 during mid-day trading on Friday, hitting $58.37. 7,883,470 shares of the company’s stock were exchanged, compared to its average volume of 5,746,147. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The business has a fifty day moving average price of $62.60 and a 200 day moving average price of $73.38. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The company has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently made changes to their positions in the business. Victory Capital Management Inc. boosted its position in shares of Tempus AI by 1.5% during the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of Tempus AI by 29.5% during the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after purchasing an additional 167 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after acquiring an additional 176 shares during the last quarter. Legacy Bridge LLC boosted its position in shares of Tempus AI by 1.6% during the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock valued at $733,000 after buying an additional 193 shares during the period. Finally, Truist Financial Corp increased its stake in Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after purchasing an additional 194 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TEM has been the subject of a number of analyst reports. BTIG Research raised their price objective on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Morgan Stanley boosted their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. JPMorgan Chase & Co. cut their target price on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Mizuho initiated coverage on Tempus AI in a research note on Thursday. They issued an “outperform” rating and a $100.00 price target for the company. Finally, HC Wainwright lowered their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $85.92.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.